CFTR Program (via Boehringer Ingelheim)
Cystic Fibrosis (CF)
Phase 1Active (by partner)
Key Facts
About AlveoGene
AlveoGene is an innovative biotech focused on transforming outcomes for patients with rare respiratory diseases through targeted, inhaled gene therapy. Its core asset is the InGenuiTy™ platform, a next-generation lentiviral vector system designed for high-efficiency transduction of lung epithelial cells, enabling durable expression and repeatable dosing. The company was formed in July 2023 by a consortium of leading UK life science investors and six world-renowned scientific founders from the UK Respiratory Gene Therapy Consortium, leveraging over £72 million in prior grant-funded research.
View full company profile